Last 12 months
Inside the activity.
6 purchase rows · 11 sale rows
Disclosed non-derivative P/S rows, by transaction month. Includes amendments and private transactions.Monthly counts
| Month | Purchases | Sales |
|---|---|---|
| Nov 2025 | 0 | 1 |
| Dec 2025 | 0 | 0 |
| Jan 2026 | 1 | 0 |
| Feb 2026 | 2 | 0 |
| Mar 2026 | 0 | 6 |
| Apr 2026 | 2 | 0 |
| May 2026 | 1 | 0 |
| Jun 2026 | 0 | 0 |
| Jul 2026 | 0 | 0 |
| Aug 2026 | 0 | 3 |
| Sep 2026 | 0 | 1 |
| Oct 2026 | 0 | 0 |
Latest available
Insider transactions
Purchases/sales include open-market and private transactions. Plan disclosure applies to the filing; individual rows may differ. “Not disclosed” is not “unplanned.”
The cutoff filters transaction history only. Company summaries and owner relationships show the latest available disclosures. Parser corrections can improve historical records.
| Transaction date | Owner / reported role | Activity / security | Shares / units | Reported price | Reported value | Details |
|---|---|---|---|---|---|---|
| February 19, 2021 Filed Feb 24, 2021 00:18 UTC |
Wellisch Alejandro DSENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 39,994 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000903 · form4-02232021_040255.xml · derivative · entry 1 Wellisch Alejandro D · CIK 0001717526 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,994 Underlying: Common Shares · 39,994 shares Expires 2031-02-18 F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 13,331 on February 19, 2022, 13,331 on February 19, 2023, and 13,332 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:20 UTC |
WHITE MILES DDirector · EXECUTIVE CHAIRMAN
|
GrantOption (right to buy) · Derivative | 227,272 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000904 · form4-02232021_040231.xml · derivative · entry 4 WHITE MILES D · CIK 0001239129 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 227,272 Underlying: Common Shares · 227,272 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 75,757 on February 19, 2022, 75,757 on February 19, 2023, and 75,758 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:20 UTC |
WHITE MILES DDirector · EXECUTIVE CHAIRMAN
|
GrantCommon shares without par value | 44,340 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000904 · form4-02232021_040231.xml · nonDerivative · entry 2 WHITE MILES D · CIK 0001239129 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,148,487 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:22 UTC |
WOODGRIFT RANDEL WILLIAMSENIOR VICE PRESIDENT
|
GrantOption (right to buy) · Derivative | 47,993 | $0.00 Strike: $124.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000905 · form4-02232021_040255.xml · derivative · entry 3 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 47,993 Underlying: Common Shares · 47,993 shares Expires 2031-02-18 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 15,997 on February 19, 2022, 15,998 on February 19, 2023, and 15,998 on February 19, 2024. Read SEC document |
| February 19, 2021 Filed Feb 24, 2021 00:22 UTC |
WOODGRIFT RANDEL WILLIAMSENIOR VICE PRESIDENT
|
GrantCommon shares without par value | 9,363 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000905 · form4-02232021_040255.xml · nonDerivative · entry 1 WOODGRIFT RANDEL WILLIAM · CIK 0001204554 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 55,630 F1 · shares: These shares represent a performance-based restricted stock award under the Abbott Laboratories 2017 Incentive Stock Program. The award has a 3-year term, with no more than 1/3 of the award vesting in any one year upon Abbott reaching a minimum return on equity target. The award includes the right to have shares withheld for tax purposes. Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:43 UTC |
Karam SammySENIOR VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 857 | $128.23 | $109,893.11 |
DisclosureSEC source: 0001415889-21-000749 · form4-02182021_020257.xml · nonDerivative · entry 1 Karam Sammy · CIK 0001766718 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,064 Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:51 UTC |
Boudreau Philip PVICE PRESIDENT
|
Tax withholdingCommon shares without par value | 943 | $128.23 | $120,920.89 |
DisclosureSEC source: 0001415889-21-000750 · form4-02182021_020216.xml · nonDerivative · entry 1 Boudreau Philip P · CIK 0001805099 · VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 21,520 Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:57 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 505 | $128.49 | $64,887.45 |
DisclosureSEC source: 0001415889-21-000751 · form4-02182021_020211.xml · nonDerivative · entry 2 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,373 Read SEC document |
| February 16, 2021 Filed Feb 18, 2021 22:57 UTC |
Moreland Mary KEXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 1,009 | $128.23 | $129,384.07 |
DisclosureSEC source: 0001415889-21-000751 · form4-02182021_020211.xml · nonDerivative · entry 1 Moreland Mary K · CIK 0001783147 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 63,878 Read SEC document |
| February 16, 2021 Filed Feb 24, 2021 00:20 UTC |
WHITE MILES DDirector · EXECUTIVE CHAIRMAN
|
GiftCommon shares without par value | 2,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000904 · form4-02232021_040231.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,104,147 Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 00:20 UTC |
MANNING JOSEPH JSENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 3,130 | $123.03 | $385,083.90 |
DisclosureSEC source: 0001415889-21-000529 · form4-02032021_040232.xml · nonDerivative · entry 3 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,681 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.03 to $123.04, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 23:56 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 31,325 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001415889-21-000535 · form4-02042021_030210.xml · derivative · entry 7 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 31,325 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 23:56 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
Tax withholdingCommon shares without par value | 18,241 | $122.54 | $2,235,252.14 |
DisclosureSEC source: 0001415889-21-000535 · form4-02042021_030210.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 175,301 Read SEC document |
| February 02, 2021 Filed Feb 4, 2021 23:56 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 31,325 | $39.12 | $1,225,434.00 |
DisclosureSEC source: 0001415889-21-000535 · form4-02042021_030210.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 193,542 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 02, 2021 Filed Feb 24, 2021 00:07 UTC |
PEDERSON MICHAEL JSENIOR VICE PRESIDENT
|
GiftCommon shares without par value | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-21-000898 · form4-02232021_040257.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 59,454 Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC |
Scoggins Christopher JSENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 15,000 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-000528 · form4-02032021_040225.xml · derivative · entry 5 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 15,000 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC |
Scoggins Christopher JSENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 30,000 | $0.00 Strike: $48.04 | $0.00 |
DisclosureSEC source: 0001415889-21-000528 · form4-02032021_040225.xml · derivative · entry 4 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 17,226 Underlying: Common Shares · 30,000 shares Expires 2025-06-14 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC |
Scoggins Christopher JSENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 45,000 | $123.24 | $5,545,800.00 |
DisclosureSEC source: 0001415889-21-000528 · form4-02032021_040225.xml · nonDerivative · entry 3 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 39,706 Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC |
Scoggins Christopher JSENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 15,000 | $38.40 | $576,000.00 |
DisclosureSEC source: 0001415889-21-000528 · form4-02032021_040225.xml · nonDerivative · entry 2 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 84,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:14 UTC |
Scoggins Christopher JSENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 30,000 | $48.04 | $1,441,200.00 |
DisclosureSEC source: 0001415889-21-000528 · form4-02032021_040225.xml · nonDerivative · entry 1 Scoggins Christopher J · CIK 0001772286 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 69,706 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 95,600 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · derivative · entry 6 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 189,788 Underlying: Common Shares · 95,600 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 107,793 | $0.00 Strike: $39.12 | $0.00 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · derivative · entry 5 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common Shares · 107,793 shares Expires 2024-02-20 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 2,050 | $124.03 | $254,256.99 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · nonDerivative · entry 4 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 151,896 F2 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $124.00 to $124.19, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
SaleCommon shares without par value | 201,343 | $123.47 | $24,858,994.70 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · nonDerivative · entry 3 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 153,946 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $123.00 to $123.99, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 95,600 | $38.40 | $3,671,040.00 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · nonDerivative · entry 2 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 355,289 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:10 UTC |
ALLEN HUBERT LEXECUTIVE VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 107,793 | $39.12 | $4,216,862.16 |
DisclosureSEC source: 0001415889-21-000526 · form4-02032021_040226.xml · nonDerivative · entry 1 ALLEN HUBERT L · CIK 0001565916 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 259,689 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:20 UTC |
MANNING JOSEPH JSENIOR VICE PRESIDENT
|
Exercise / conversionOption (right to buy) · Derivative | 18,750 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001415889-21-000529 · form4-02032021_040232.xml · derivative · entry 4 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 18,750 Underlying: Common Shares · 18,750 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:20 UTC |
MANNING JOSEPH JSENIOR VICE PRESIDENT
|
SaleCommon shares without par value | 18,750 | $122.79 | $2,302,263.75 |
DisclosureSEC source: 0001415889-21-000529 · form4-02032021_040232.xml · nonDerivative · entry 2 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 62,811 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $122.75 to $122.8250, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| February 01, 2021 Filed Feb 4, 2021 00:20 UTC |
MANNING JOSEPH JSENIOR VICE PRESIDENT
|
Exercise / conversionCommon shares without par value | 18,750 | $38.40 | $720,000.00 |
DisclosureSEC source: 0001415889-21-000529 · form4-02032021_040232.xml · nonDerivative · entry 1 MANNING JOSEPH J · CIK 0001695686 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 81,561 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 23:32 UTC |
Alpern Robert JDirector
|
GrantStock Equivalent Units · Derivative | 71 | $109.49 | $7,773.79 |
DisclosureSEC source: 0001415889-21-000152 · form4-01052021_030112.xml · derivative · entry 1 Alpern Robert J · CIK 0001448074 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 8,214 Underlying: Common Shares · 71 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 31, 2020 Filed Jan 5, 2021 23:36 UTC |
Stratton John GDirector
|
GrantStock Equivalent Units · Derivative | 287 | $109.49 | $31,423.63 |
DisclosureSEC source: 0001415889-21-000153 · form4-01052021_030153.xml · derivative · entry 1 Stratton John G · CIK 0001385262 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 6,049 Underlying: Common Shares · 287 shares Expires not disclosed F1 · derivative.exercise_price: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.exercise_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F1 · derivative.expiration_date: Director fees credited to a stock equivalent unit account under a grantor trust established by the director and paid, in cash, generally at age 65 or upon retirement from the board. The stock equivalent units earn the same return as if the fees were invested in Abbott stock. F2 · balance_after: Balance includes stock equivalent units acquired pursuant to a dividend reinvestment feature. Read SEC document |
| December 21, 2020 Filed Dec 31, 2020 22:32 UTC |
PEDERSON MICHAEL JSENIOR VICE PRESIDENT
|
OtherCommon shares without par value | 75 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-003073 · form4-12312020_021212.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Indirect · By Spouse Disclosed balance after: 75 Read SEC document |
| December 15, 2020 Filed Dec 19, 2020 00:12 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
GiftCommon shares without par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002992 · form4-12182020_041255.xml · nonDerivative · entry 3 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 10,000 F1 · balance_after: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust. Read SEC document |
| December 15, 2020 Filed Dec 19, 2020 00:12 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
GiftCommon shares without par value | 10,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002992 · form4-12182020_041255.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Indirect · By Trust Disclosed balance after: 10,000 F1 · balance_after: Held in daughter's annual gift trust. The reporting person disclaims beneficial ownership of all securities held by the trust. Read SEC document |
| December 15, 2020 Filed Dec 19, 2020 00:12 UTC |
Funck, Jr. Robert E.EXECUTIVE VICE PRESIDENT
|
GiftCommon shares without par value | 20,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002992 · form4-12182020_041255.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · EXECUTIVE VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 162,217 Read SEC document |
| December 15, 2020 Filed Dec 19, 2020 00:14 UTC |
PEDERSON MICHAEL JSENIOR VICE PRESIDENT
|
GiftCommon shares without par value | 6,000 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002993 · form4-12182020_041240.xml · nonDerivative · entry 1 PEDERSON MICHAEL J · CIK 0001712233 · SENIOR VICE PRESIDENT 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 65,454 Read SEC document |
| December 07, 2020 Filed Dec 19, 2020 00:07 UTC |
WHITE MILES DDirector · EXECUTIVE CHAIRMAN
|
GiftCommon shares without par value | 1,844 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002991 · form4-12182020_041241.xml · nonDerivative · entry 3 WHITE MILES D · CIK 0001239129 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,106,147 Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 22:58 UTC |
NOVAKOVIC PHEBE NDirector
|
Exercise / conversionOption (right to buy) · Derivative | 11,348 | $0.00 Strike: $36.48 | $0.00 |
DisclosureSEC source: 0001415889-20-002858 · form4-12082020_021215.xml · derivative · entry 5 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 11,348 shares Expires 2023-04-25 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 22:58 UTC |
NOVAKOVIC PHEBE NDirector
|
Exercise / conversionOption (right to buy) · Derivative | 3,333 | $0.00 Strike: $29.84 | $0.00 |
DisclosureSEC source: 0001415889-20-002858 · form4-12082020_021215.xml · derivative · entry 4 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 3,333 shares Expires 2022-04-26 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F2 · security: Stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 22:58 UTC |
NOVAKOVIC PHEBE NDirector
|
SaleCommon shares without par value | 4,790 | $107.28 | $513,849.17 |
DisclosureSEC source: 0001415889-20-002858 · form4-12082020_021215.xml · nonDerivative · entry 3 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 41,004 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $107.275 to $107.285, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 22:58 UTC |
NOVAKOVIC PHEBE NDirector
|
Exercise / conversionCommon shares without par value | 11,348 | $36.48 | $413,975.04 |
DisclosureSEC source: 0001415889-20-002858 · form4-12082020_021215.xml · nonDerivative · entry 2 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 45,794 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2020 Filed Dec 8, 2020 22:58 UTC |
NOVAKOVIC PHEBE NDirector
|
Exercise / conversionCommon shares without par value | 3,333 | $29.84 | $99,456.05 |
DisclosureSEC source: 0001415889-20-002858 · form4-12082020_021215.xml · nonDerivative · entry 1 NOVAKOVIC PHEBE N · CIK 0001222195 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 34,446 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| December 04, 2020 Filed Dec 19, 2020 00:07 UTC |
WHITE MILES DDirector · EXECUTIVE CHAIRMAN
|
GiftCommon shares without par value | 64,978 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002991 · form4-12182020_041241.xml · nonDerivative · entry 2 WHITE MILES D · CIK 0001239129 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,107,991 Read SEC document |
| December 03, 2020 Filed Dec 19, 2020 00:07 UTC |
WHITE MILES DDirector · EXECUTIVE CHAIRMAN
|
GiftCommon shares without par value | 7,974 | $0.00 | $0.00 |
DisclosureSEC source: 0001415889-20-002991 · form4-12182020_041241.xml · nonDerivative · entry 1 WHITE MILES D · CIK 0001239129 · Director · EXECUTIVE CHAIRMAN 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 3,172,969 Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 22:41 UTC |
OSBORN WILLIAM ADirector
|
Exercise / conversionOption (right to buy) · Derivative | 21,448 | $0.00 Strike: $43.64 | $0.00 |
DisclosureSEC source: 0001179110-20-011416 · edgar.xml · derivative · entry 2 OSBORN WILLIAM A · CIK 0001171797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 21,448 shares Expires 2027-04-27 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F1 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| November 24, 2020 Filed Nov 25, 2020 22:41 UTC |
OSBORN WILLIAM ADirector
|
Exercise / conversionCommon shares without par value | 21,448 | $43.64 | $935,990.72 |
DisclosureSEC source: 0001179110-20-011416 · edgar.xml · nonDerivative · entry 1 OSBORN WILLIAM A · CIK 0001171797 · Director 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 79,745 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 22:33 UTC |
Funck, Jr. Robert E.Executive Vice President & CFO
|
Exercise / conversionOption (right to buy) · Derivative | 83,333 | $0.00 Strike: $38.40 | $0.00 |
DisclosureSEC source: 0001179110-20-010699 · edgar.xml · derivative · entry 6 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 0 Underlying: Common shares · 83,333 shares Expires 2026-02-18 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. F4 · security: Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 22:33 UTC |
Funck, Jr. Robert E.Executive Vice President & CFO
|
SaleCommon shares without par value | 83,333 | $108.83 | $9,068,955.39 |
DisclosureSEC source: 0001179110-20-010699 · edgar.xml · nonDerivative · entry 2 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 182,217 F1 · price: The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $108.75 to $108.93, inclusive. The reporting person undertakes to provide to Abbott Laboratories, any security holder of Abbott Laboratories, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote. Read SEC document |
| October 26, 2020 Filed Oct 28, 2020 22:33 UTC |
Funck, Jr. Robert E.Executive Vice President & CFO
|
Exercise / conversionCommon shares without par value | 83,333 | $38.40 | $3,199,987.20 |
DisclosureSEC source: 0001179110-20-010699 · edgar.xml · nonDerivative · entry 1 Funck Robert E · CIK 0001565892 · Executive Vice President & CFO 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 265,550 Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event. Read SEC document |
| October 01, 2020 Filed Oct 5, 2020 21:50 UTC |
Ahlberg Gregory ASenior Vice President
|
GrantOption (right to buy) · Derivative | 9,084 | $0.00 Strike: $109.36 | $0.00 |
DisclosureSEC source: 0001179110-20-010243 · edgar.xml · derivative · entry 3 Ahlberg Gregory A · CIK 0001826317 · Senior Vice President 10b5-1 filing: Not disclosed Ownership: Direct Disclosed balance after: 9,084 Underlying: Common Shares · 9,084 shares Expires 2030-09-30 F3 · security: Employee stock option granted pursuant to the Abbott Laboratories 2017 Incentive Stock Program in a transaction exempt from Section 16 under Rule 16b-3. The option becomes exercisable in annual increments of 3,028 on each of October 1, 2021, October 1, 2022 and October 1, 2023. Read SEC document |
Value uses the disclosed total when available, otherwise shares × reported transaction price. It is not an estimate of exercise cash cost or investment performance.